Drug delivery platform buccal administration passage BBB, water-soluble APIs RNAi peptides metal ions
Total Trials
7
As Lead Sponsor
5
As Collaborator
2
Total Enrollment
407
NCT00768287
Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B
Phase: Phase 2/3
Role: Lead Sponsor
Start: Jan 31, 2009
Completion: Dec 31, 2016
NCT01271868
Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B
Phase: Phase 3
Start: Nov 30, 2010
NCT03855280
Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B
Start: Jan 16, 2020
Completion: Jul 4, 2022
NCT05451654
NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)
Phase: Phase 1/2
Start: Feb 4, 2022
Completion: Dec 1, 2022
NCT05423522
Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease
Phase: Phase 2
Start: May 20, 2022
Completion: Oct 29, 2024
NCT04994808
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
Role: Collaborator
Start: Aug 11, 2023
Completion: Jul 16, 2026
NCT06875258
PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)
Phase: Phase 4
Start: Jan 15, 2024
Completion: Jan 1, 2027
Loading map...